|Seattle Genetics to Present at Needham Healthcare Conference|
BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 29, 2012--
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management
will present at the upcoming 11th Annual Needham Healthcare
Conference in New York, NY. The presentation is scheduled for Tuesday,
April 3, at 10:00 a.m. Eastern time. It will be webcast live and
available for replay from Seattle Genetics’ website at www.seattlegenetics.com
in the Investors
and News section.
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development
and commercialization of monoclonal antibody-based therapies for the
treatment of cancer. The U.S. Food and Drug Administration granted
accelerated approval of ADCETRIS in August 2011 for two indications.
ADCETRIS is being developed in collaboration with Millennium: The Takeda
Oncology Company. In addition, Seattle Genetics has three other
clinical-stage ADC programs: SGN-75, ASG-5ME and ASG-22ME. Seattle
Genetics has collaborations for its ADC technology with a number of
leading biotechnology and pharmaceutical companies, including Abbott,
Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline,
Millennium, Pfizer and Progenics, as well as ADC co-development
agreements with Agensys, an affiliate of Astellas, and Genmab. More
information can be found at www.seattlegenetics.com.
Source: Seattle Genetics, Inc.
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
© 2012 Seattle Genetics, Inc.